Latest Healthcare It News

Page 4 of 142
Third Age Health lifted first-half revenue 20.8% and statutory profit 38.4% as aged medical care services supplied almost all of the growth. The NZX-listed healthcare provider maintained its 4 cents per share quarterly dividend while warning that cybersecurity and technology investment could weigh on near-term earnings.
Ada Torres
Ada Torres
30 Oct 2026
Oakridge International reported a $267,000 operating cash outflow for the September quarter, leaving $343,000 in cash and an estimated 1.28 quarters of funding. The healthcare technology company expects collections and customer orders to improve cash flow, while evaluating additional funding and continuing to manage a potential historical claim from Teko International.
Victor Sage
Victor Sage
30 Oct 2026
BCAL Diagnostics has completed clinical validation for BREASTESTplus 2 across all breast densities and is targeting a November launch, while expanding Avantect Multicancer access. The commercial push comes alongside $1.895 million in quarterly operating cash outflows, only $580,000 in cash at quarter end and a growing strategic stake in Genetic Signatures.
Ada Torres
Ada Torres
30 Oct 2026
Epsilon Healthcare delivered record September-quarter customer receipts of A$3.9 million, while nine-month revenue reached A$11.5 million. The growth story is strengthening, but cash fell to A$997,000 and quarterly operating cash flow remained negative.
Ada Torres
Ada Torres
30 Oct 2026
Hydralyte LLC recorded its first monthly operating profit in August, while a major cost reset cut its quarterly operating loss to US$66,900. But revenue fell 21.9%, cash narrowed to US$173,400 and the company is seeking up to A$1.4 million through a rights issue.
Victor Sage
Victor Sage
30 Oct 2026
Vitasora Health has signed a Florida healthcare agreement covering an initially addressable 9,000 Medicare patients while estimated October billable care minutes rose 50%. The ASX-listed company also agreed terms for an A$3 million secured facility, but the funding is not yet drawn and carries approval, interest and dilution conditions.
Ada Torres
Ada Torres
30 Oct 2026
Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.
Victor Sage
Victor Sage
30 Oct 2026
Emyria has reported record quarterly revenue of approximately $1.42 million after opening its first Sydney Empax clinic and expanding national treatment capacity. The growth comes with $2.28 million in operating cash outflows and an estimated 2.08 quarters of funding at quarter-end.
Ada Torres
Ada Torres
29 Oct 2026
Atomo Diagnostics has signed an MOU with Innovation Scientific to develop a fourth-generation HIV rapid test using its Galileo cassette. The project could add a new product to Atomo’s pipeline, but regulatory approval, clinical work and definitive commercial agreements remain outstanding.
Ada Torres
Ada Torres
29 Oct 2026
Alcidion has started FY27 with contracted revenue up 38% to $50.0 million, while a major UK expansion and new patient administration product widen its growth case. The company has also reaffirmed that FY27 revenue and underlying EBITDA will exceed FY26, but its capital plan now has several competing demands.
Victor Sage
Victor Sage
29 Oct 2026
PainChek is concentrating its commercial effort on residential aged care after signing new US and UK business, including an 808-licence Sabra expansion and an approximately 1,800-licence Hallmark contract. Revenue and retention improved, but activated ARR growth slowed to 1.2% for the quarter and cash covered an estimated 2.5 quarters of historical operating outflows.
Victor Sage
Victor Sage
28 Oct 2026
Dexus has forecast lower FY27 earnings while refocusing its business on office, industrial, retail and selected alternatives. The ASX-listed real estate group is also targeting more than A$2 billion of capital release, but remains exposed to infrastructure fund liquidity issues and the unresolved APAC appeal.
Eva Park
Eva Park
28 Oct 2026

Browse the archive

Full archive